Reach Us +44-1202-068036
Possible Protective Role Of Erythropoietin In Vincristine-induced Central Toxicity In Rat | 37510
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Possible protective role of erythropoietin in vincristine-induced central toxicity in rat

Pharma Middle East

Malak Abouayana, Aya Naiel and Dalia A Hamdy

Alexandria University, Egypt

Posters-Accepted Abstracts: Clin Pharmacol Biopharm

DOI: 10.4172/2167-065X.C1.014

Aim: 1. To develop a rat model to study vincristine-induced SAIDH 2. To determine the possible role of erythropoietin in reducing the hyponatremia and survival rate associated with vincristine-induced SAIDH. Methods: Rats were allocated into five groups (n=4-8 each). All groups were i.p. dosed 0.15 ug/Kg vincristine sulphate (VCR) for 15 days 6 days per week. Groups 2, 3 and 5 were administered either 40 U/Kg or 80 U/Kg erythropoietin i.p. along with the VCR. Groups 4 and 5 were administered 40 mg/Kg posaconazole (PSZ) orally starting the day of VCR administration. Rats’ weights and survival rates were measured daily and their serum sodium and potassium levels were measured at days 0, 5, 9 and 15. Results: No rats survived after day 12 of dosing. The VCR-induced SAIDH rat model showed 3.4% and 4.1% reduced sodium levels on days 5 & 9, respectively. Their serum potassium level showed no significant change on day 5 and 8% decrease on day 9. The rats exhibited weight reduction of 10% and 18% on days 5 and 9, respectively. Erythropoietin 40 U/Kg treated rats showed significantly less hyponatremia (0.6% decrease) and 24% increase in potassium levels on day 5. However, increasing the erythropoietin therapy duration beyond 5 days and/or dose (80 U/Kg treated groups) resulted in increased hyponatremia and demolished rats’ survival. PSZ-VCR dosed rats and PSZ-VCR-erythropoietin dosed rats survived only for 4 days. Posaconazole-VCR treated groups showed increased VCR toxicity with ~12% increase in serum potassium levels, however, serum sodium levels showed no significant difference during the 4 days. Conclusion: Initial rat model to study vincristine-induced SAIDH was developed. Co-administration of low dose erythropoietin (40 U/Kg) for short duration, ≤5 days, showed a potential benefit in reversing the VCR-induced hyponatremia however, we need to consider controlling the induced hyperkalemia. Human serum sodium, potassium and BUN levels for patients administered VCR alone or VCR along with erythropoietin in ALL treatment protocols needs to be studied to confirm such trends.

Malak Abouayana is a third-year undergraduate pharmacy student, Faculty of Pharmacy, Alexandria University.

Email: [email protected]

Leave Your Message 24x7